PL3082860T3 - Sposób leczenia ran - Google Patents

Sposób leczenia ran

Info

Publication number
PL3082860T3
PL3082860T3 PL14871427T PL14871427T PL3082860T3 PL 3082860 T3 PL3082860 T3 PL 3082860T3 PL 14871427 T PL14871427 T PL 14871427T PL 14871427 T PL14871427 T PL 14871427T PL 3082860 T3 PL3082860 T3 PL 3082860T3
Authority
PL
Poland
Prior art keywords
treating wounds
wounds
treating
Prior art date
Application number
PL14871427T
Other languages
English (en)
Polish (pl)
Inventor
Ulf Eriksson
Annelie FALKEVALL
Annika MEHLEM
Original Assignee
Csl Limited
B-Creative Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013904942A external-priority patent/AU2013904942A0/en
Application filed by Csl Limited, B-Creative Sweden Ab filed Critical Csl Limited
Publication of PL3082860T3 publication Critical patent/PL3082860T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14871427T 2013-12-18 2014-12-18 Sposób leczenia ran PL3082860T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2013904942A AU2013904942A0 (en) 2013-12-18 Method of treating wounds
AU2013904966A AU2013904966A0 (en) 2013-12-19 Method of treating wounds
EP14871427.2A EP3082860B1 (en) 2013-12-18 2014-12-18 Method of treating wounds
PCT/AU2014/050431 WO2015089585A1 (en) 2013-12-18 2014-12-18 Method of treating wounds

Publications (1)

Publication Number Publication Date
PL3082860T3 true PL3082860T3 (pl) 2021-06-14

Family

ID=53401804

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14871427T PL3082860T3 (pl) 2013-12-18 2014-12-18 Sposób leczenia ran

Country Status (13)

Country Link
US (1) US10543270B2 (enExample)
EP (1) EP3082860B1 (enExample)
JP (1) JP6553618B2 (enExample)
KR (2) KR102466794B1 (enExample)
CN (1) CN105979965B (enExample)
AU (1) AU2014366837B2 (enExample)
BR (1) BR112016014099A2 (enExample)
CA (1) CA2932465C (enExample)
DK (1) DK3082860T3 (enExample)
ES (1) ES2851386T3 (enExample)
PL (1) PL3082860T3 (enExample)
RU (1) RU2672377C1 (enExample)
WO (1) WO2015089585A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106681B (zh) 2014-11-17 2021-11-09 Csl有限公司 治疗或预防中风的方法
RU2018139893A (ru) * 2016-04-21 2020-05-21 СиЭсЭл ЛИМИТЕД Способ лечения или предупреждения болезней печени
WO2023115112A1 (en) * 2021-12-20 2023-06-29 CSL Innovation Pty Ltd Protein formulations and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
US5844094A (en) 1992-09-25 1998-12-01 Commonwealth Scientific And Industrial Research Organization Target binding polypeptide
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
PL343064A1 (en) 1998-03-20 2001-07-30 Benitec Australia Ltd Control of gene expression
AU760041B2 (en) 1998-04-08 2003-05-08 Commonwealth Scientific And Industrial Research Organisation Methods and means for obtaining modified phenotypes
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
AU2002256371B2 (en) 2001-04-26 2008-01-10 Amgen Mountain View Inc. Combinatorial libraries of monomer domains
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US20050163781A1 (en) * 2002-01-29 2005-07-28 Philippe Koninckx Tissue adhesion formation control
US20040005671A1 (en) * 2002-05-17 2004-01-08 Amrad Operations Pty Ltd. Immunointeractive molecules
US20030232439A1 (en) 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US20070292416A1 (en) 2003-06-02 2007-12-20 Alexion Pharmaceuticals, Inc. De-Immunized Anti-Cd3 Antibody
US7993650B2 (en) 2003-07-04 2011-08-09 Affibody Ab Polypeptides having binding affinity for HER2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
EP1751181B1 (en) 2004-06-02 2012-08-15 AdAlta Pty Ltd BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS
PL1781321T3 (pl) * 2004-08-02 2014-07-31 Zenyth Operations Pty Ltd Sposób leczenia raka zawierający antagonistę VEGF-B
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007019620A1 (en) 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
WO2007140534A1 (en) * 2006-06-08 2007-12-13 Csl Limited Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
AU2008219065B2 (en) * 2007-02-19 2014-01-30 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
WO2009045356A2 (en) 2007-09-28 2009-04-09 Yale University Microrna compositions in the treatment of vegf-mediated disorders
EP2271365A4 (en) * 2008-04-09 2011-10-26 Ludwig Inst Cancer Res REGULATION OF FATTY ACID TRANSPORTERS
SG10201510586PA (en) * 2008-06-30 2016-01-28 Mesoblast Inc Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
RU2395521C1 (ru) * 2008-11-10 2010-07-27 Учреждение Российской Академии Наук Институт Биологии Гена Ран Наноантитело v9, связывающее vegf, и способ его получения, кодирующая v9 нуклеотидная последовательность и содержащий ее вектор, способ ингибирования пролиферации эндотелиальных клеток
PL2786762T3 (pl) 2008-12-19 2019-09-30 Macrogenics, Inc. Kowalencyjne diabody i ich zastosowania
US9259507B2 (en) * 2009-04-21 2016-02-16 Warsaw Orthopedic, Inc. Tissue augmentation with active agent for wound healing
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires

Also Published As

Publication number Publication date
KR102466794B1 (ko) 2022-11-11
RU2016127196A (ru) 2018-01-23
CA2932465A1 (en) 2015-06-25
JP6553618B2 (ja) 2019-07-31
DK3082860T3 (da) 2021-01-25
RU2672377C1 (ru) 2018-11-14
JP2017501182A (ja) 2017-01-12
CN105979965B (zh) 2021-07-09
KR20160096194A (ko) 2016-08-12
EP3082860A4 (en) 2017-08-16
CA2932465C (en) 2023-08-22
EP3082860B1 (en) 2020-11-25
KR20220115815A (ko) 2022-08-18
ES2851386T3 (es) 2021-09-06
AU2014366837B2 (en) 2020-06-25
EP3082860A1 (en) 2016-10-26
US10543270B2 (en) 2020-01-28
CN105979965A (zh) 2016-09-28
US20160319008A1 (en) 2016-11-03
BR112016014099A2 (pt) 2017-10-10
WO2015089585A1 (en) 2015-06-25
AU2014366837A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
ZA201505926B (en) Wound dressing and method of treatment
ZA201505956B (en) Methods of treating melanoma
PT2992908T (pt) Método para tratamento da superfície do implante
EP3057594A4 (en) Method of treating cancer
ZA201506534B (en) Method of treating hair
SG11201508878WA (en) Methods of treating cancer
EP3074040A4 (en) Method of treating cancer
IL242678B (en) A method for treating intracellular infection
GB201308466D0 (en) Improved process for treatment of minewater
ZA201507762B (en) Methods of treating cancer
EP3074038A4 (en) Method of treating nephropathy
GB201305231D0 (en) Method of Manufacture
IL241096B (en) Treatment methods
GB2518928B (en) Method of depilation
EP2994461A4 (en) Methods of treating skin conditions using cyclolignan compounds
PL3082860T3 (pl) Sposób leczenia ran
EP2985265A4 (en) PROCESS FOR TREATING RESIDUAL WATER
PL3041506T3 (pl) Sposób leczenia
AU2013904966A0 (en) Method of treating wounds
AU2013904942A0 (en) Method of treating wounds
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment
ZA201408732B (en) Composition and methods for treating wounds
AU2013904712A0 (en) Method of Treatment
AU2013904170A0 (en) Method of treatment